Independent Market Access and Reimbursement Risk Assessment.

Built by former payers, HTA reviewers, and Industry Experts.

Archives: Reports

MARA Rating Company
December 16, 2025

Pembrolizumab / keytruda for the first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with a CPS of 1 or more as of June 2024

MARA Rating Company December 16, 2025

Pembrolizumab / keytruda for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma as of August 2024

MARA Rating Company December 16, 2025

Pembrolizumab / keytruda for treating resectable non-small-cell lung cancer as of November 2024

MARA Rating Company December 16, 2025

Pembrolizumab / keytruda for adjuvant treatment of resected non-small-cell lung cancer as of February 2025

MARA Rating Company December 16, 2025

Pembrolizumab for untreated, metastatic, non-squamous non-small-cell lung cancer as of March 2021

MARA Rating Company December 16, 2025

Pembrolizumab / keytruda for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy as of April 2021

MARA Rating Company December 16, 2025

Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency as of June 2021

MARA Rating Company December 16, 2025

Keytruda / pembrolizumab for untreated locally advanced unresectable or metastatic carcinoma of the oesophagus in adults whose tumours express PD-L1 with a CPS of 10 or more as of August 2024

MARA Rating Company December 16, 2025

Pembrolizumab / keytruda for adjuvant treatment of completely resected stage 3 melanoma with lymph node involvement as of February 2022

MARA Rating Company December 16, 2025

Pembrolizumab / keytruda for untreated metastatic squamous non-small-cell lung cancer as of February 2022

MARA Rating Company December 16, 2025